{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:11:19Z","timestamp":1778721079712,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-026-02257-3","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:17:58Z","timestamp":1775229478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of replacement versus suppressive doses of levothyroxine on bone mineral density"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-7900","authenticated-orcid":false,"given":"Mahmood","family":"Parham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6228-6364","authenticated-orcid":false,"given":"Mohammad","family":"Bagherzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1738-6856","authenticated-orcid":false,"given":"Seyed Mohammad Hossein","family":"Miri Ashtiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0377-3351","authenticated-orcid":false,"given":"Bita","family":"Bitarafan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5044-2179","authenticated-orcid":false,"given":"Elham","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3417-1580","authenticated-orcid":false,"given":"Mohammad","family":"Aghaali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"10","key":"2257_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/1060028018768808","volume":"52","author":"P Morizio","year":"2018","unstructured":"Morizio P, Burkhart JI, Ozawa S. Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients. Ann Pharmacother. 2018;52(10):1031\u201341.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"2257_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40273-020-00965-9","volume":"39","author":"N Li","year":"2021","unstructured":"Li N, Cornelissen D, Silverman S, Pinto D, Si L, Kremer I, Bours S, de Bot R, Boonen A, Evers S, et al. An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis. PharmacoEconomics. 2021;39(2):181\u2013209.","journal-title":"PharmacoEconomics"},{"issue":"12","key":"2257_CR3","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726\u201333.","journal-title":"Osteoporos Int"},{"issue":"1","key":"2257_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1):136.","journal-title":"Arch Osteoporos"},{"issue":"5","key":"2257_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","volume":"11","author":"A Parthan","year":"2013","unstructured":"Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy. 2013;11(5):485\u201397.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"2257_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1210\/edrv.23.1.0455","volume":"23","author":"AC Bianco","year":"2002","unstructured":"Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23(1):38\u201389.","journal-title":"Endocr Rev"},{"issue":"2","key":"2257_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/8756-3282(86)90681-2","volume":"7","author":"EF Eriksen","year":"1986","unstructured":"Eriksen EF, Mosekilde L, Melsen F. Kinetics of trabecular bone resorption and formation in hypothyroidism: evidence for a positive balance per remodeling cycle. Bone. 1986;7(2):101\u20138.","journal-title":"Bone"},{"issue":"1","key":"2257_CR8","first-page":"56","volume":"86","author":"L Mosekilde","year":"1978","unstructured":"Mosekilde L, Melsen F. Morphometric and dynamic studies of bone changes in hypothyroidism. Acta Pathol Microbiol Scand A. 1978;86(1):56\u201362.","journal-title":"Acta Pathol Microbiol Scand A"},{"issue":"1","key":"2257_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40618-017-0753-4","volume":"41","author":"GR Williams","year":"2018","unstructured":"Williams GR, Bassett JHD. Thyroid diseases and bone health. J Endocrinol Invest. 2018;41(1):99\u2013109.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2257_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0889-8529(18)30338-4","volume":"19","author":"L Mosekilde","year":"1990","unstructured":"Mosekilde L, Eriksen EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am. 1990;19(1):35\u201363.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"2257_CR11","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1210\/jc.2010-2135","volume":"96","author":"SP Bours","year":"2011","unstructured":"Bours SP, van Geel TA, Geusens PP, Janssen MJ, Janzing HM, Hoffland GA, Willems PC, van den Bergh JP. Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a clinical fracture. J Clin Endocrinol Metab. 2011;96(5):1360\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2257_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12902-024-01819-7","volume":"25","author":"X Li","year":"2025","unstructured":"Li X, Zhang T, Zhang H, Liu S, Tian L. Effects of levothyroxine therapy on bone and mineral metabolism in hypothyroidism: a systematic review and meta-analysis. BMC Endocr Disord. 2025;25(1):11.","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"2257_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1210\/er.2015-1106","volume":"37","author":"JH Bassett","year":"2016","unstructured":"Bassett JH, Williams GR. Role of Thyroid Hormones in Skeletal Development and Bone Maintenance. Endocr Rev. 2016;37(2):135\u201387.","journal-title":"Endocr Rev"},{"issue":"4","key":"2257_CR14","first-page":"818","volume":"78","author":"C Marcocci","year":"1994","unstructured":"Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab. 1994;78(4):818\u201323.","journal-title":"J Clin Endocrinol Metab"},{"key":"2257_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bone.2014.10.009","volume":"71","author":"MK Kim","year":"2015","unstructured":"Kim MK, Yun KJ, Kim MH, Lim DJ, Kwon HS, Song KH, Kang MI, Baek KH. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Bone. 2015;71:101\u20135.","journal-title":"Bone"},{"issue":"3","key":"2257_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.11005\/jbm.2015.22.3.135","volume":"22","author":"CW Kim","year":"2015","unstructured":"Kim CW, Hong S, Oh SH, Lee JJ, Han JY, Hong S, Kim SH, Nam M, Kim YS. Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma. J Bone Metab. 2015;22(3):135\u201341.","journal-title":"J Bone Metab"},{"issue":"4","key":"2257_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00774-015-0680-4","volume":"34","author":"M Mendon\u00e7a","year":"2016","unstructured":"Mendon\u00e7a M, de Barros G, Madeira M, Vieira Neto L, de Paula Paranhos Neto F, Carvalho Mendon\u00e7a LM, Corr\u00eaa Barbosa Lima I, Corbo R, Fleiuss Farias ML. Bone mineral density and bone microarchitecture after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients. J Bone Min Metab. 2016;34(4):417\u201321.","journal-title":"J Bone Min Metab"},{"issue":"4","key":"2257_CR18","first-page":"350","volume":"67","author":"L Vera","year":"2016","unstructured":"Vera L, Gay S, Campomenosi C, Paolino S, Pera G, Monti E, Mortara L, Seriolo B, Giusti M. Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy. Endokrynol Pol. 2016;67(4):350\u20138.","journal-title":"Endokrynol Pol"},{"key":"2257_CR19","doi-asserted-by":"crossref","unstructured":"Zanella AB, Marmitt L, Fighera TM, Scheffel RS, Spritzer PM, Dora JM, Maia AL. Effect of suppressive levothyroxine therapy on bone mineral density in young patients with differentiated thyroid carcinoma. Metabolites 2022;12(9).","DOI":"10.3390\/metabo12090842"},{"issue":"1","key":"2257_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1530\/eje.1.01933","volume":"153","author":"AC Heijckmann","year":"2005","unstructured":"Heijckmann AC, Huijberts MS, Geusens P, de Vries J, Menheere PP, Wolffenbuttel BH. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol. 2005;153(1):23\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2257_CR21","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1634\/theoncologist.2019-0234","volume":"24","author":"M Papaleontiou","year":"2019","unstructured":"Papaleontiou M, Banerjee M, Reyes-Gastelum D, Hawley ST, Haymart MR. Risk of Osteoporosis and Fractures in Patients with Thyroid Cancer: A Case-Control Study in U.S. Veterans. Oncologist. 2019;24(9):1166\u201373.","journal-title":"Oncologist"},{"issue":"11","key":"2257_CR22","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.3390\/cancers12113094","volume":"12","author":"CL Shapiro","year":"2020","unstructured":"Shapiro CL. Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments. Cancers (Basel). 2020;12(11):3094.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2257_CR23","first-page":"3655","volume":"106","author":"EJ Ku","year":"2021","unstructured":"Ku EJ, Yoo WS, Lee EK, Ahn HY, Woo SH, Hong JH, Chung HK, Park J-W. Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis. J Clin Endocrinol Metabolism. 2021;106(12):3655\u201367.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"2","key":"2257_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4174\/astr.2014.86.2.55","volume":"86","author":"MY Lee","year":"2014","unstructured":"Lee MY, Park JH, Bae KS, Jee YG, Ko AN, Han YJ, Shin JY, Lim JS, Chung CH, Kang SJ. Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer. Ann Surg Treat Res. 2014;86(2):55\u201360.","journal-title":"Ann Surg Treat Res"},{"issue":"1","key":"2257_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.11005\/jbm.2019.26.1.45","volume":"26","author":"Y Lee","year":"2019","unstructured":"Lee Y, Yoon BH, Lee S, Chung YK, Lee YK. Risk of Osteoporotic Fractures after Thyroid-stimulating Hormone Suppression Therapy in Patients with Thyroid Cancer. J Bone Metab. 2019;26(1):45\u201350.","journal-title":"J Bone Metab"},{"issue":"3","key":"2257_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.5114\/aoms.2010.14264","volume":"6","author":"HM Salama","year":"2010","unstructured":"Salama HM, El-Dayem SA, Yousef H, Fawzy A, Abou-Ismail L, El-Lebedy D. The effects of L-thyroxin replacement therapy on bone minerals and body composition in hypothyroid children. Arch Med Sci. 2010;6(3):407\u201313.","journal-title":"Arch Med Sci"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02257-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02257-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02257-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:29:11Z","timestamp":1778718551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-026-02257-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2257"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02257-3","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all of the participants of the study. All methods in the current research were performed in accordance with the declaration of Helsinki\u2019s guidelines and regulations. The protocol of the current study has been approved by the ethics committee of Qom University of Medical Sciences (IR.MUQ.REC.1401.080).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}